The Euro-EWING99-R1 trial asked whether cyclophosphamide may replace ifosfamide in combination with vincristine and dactinomycin ( vincristine , dactinomycin , and cyclophosphamide [ VAC ] v vincristine , dactinomycin , and ifosfamide [ VAI ] ) after an intensive induction chemotherapy containing vincristine , ifosfamide , doxorubicin , and etoposide ( VIDE ) in standard-risk localized disease ( NCT00020566 ) .